Nicotinamide mononucleotide (NMN) is a precursor to NAD+, a molecule involved in cellular energy metabolism that declines with age — which is the basis for NMN’s popularity in the longevity-supplement space. But NMN is also a useful case study in why checking the regulatory status of an ingredient matters just as much as reading the lab research.
In the United States, the FDA has taken the position that NMN does not qualify for marketing as a dietary supplement, because it was first authorized for investigation as a new drug before being marketed as a supplement — a specific exclusion under U.S. supplement law. This has led to inconsistent availability and labeling across brands and markets, and it’s a meaningfully different situation from an established, uncontested ingredient like magnesium or vitamin D.
None of this means the underlying NAD+ research is invalid — cellular NAD+ decline with age is a genuinely active area of aging research. It does mean that claims made about NMN supplements specifically deserve more scrutiny than usual, and checking current regulatory status in your own market before buying is a reasonable, non-alarmist precaution.
Official source: U.S. Food & Drug Administration — Dietary Supplement Ingredient Advisory List
This article is for informational purposes only and is not medical advice. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Talk to a healthcare provider before starting any new supplement, especially if you are pregnant, nursing, taking medication, or managing a health condition.